| |
Breast cancera
|
HR+/HER2–a
|
HR+/HER2+b
|
HR–/HER2−c
|
HR–/HER2+d
|
---|
Any NSAIDe
|
No NSAID past 3 years
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
Former/irregular
|
Cases, n
|
154
|
105
|
11
|
12
|
5
|
HRR
|
1.04
|
1.04
|
1.11
|
0.79
|
1.03
|
95% CI
|
0.86–1.24
|
0.83–1.29
|
0.56–2.20
|
0.42–1.48
|
0.38–2.81
|
Current, 3+ tablets/week
|
Cases, n
|
692
|
481
|
65
|
58
|
18
|
HRR
|
0.90
|
0.91
|
1.30
|
0.77
|
0.74
|
95% CI
|
0.80–1.01
|
0.79–1.05
|
0.86–1.98
|
0.53–1.12
|
0.38–1.45
|
Unknown
|
Cases, n
|
97
|
63
|
9
|
13
|
4
|
HRR
|
1.16
|
1.09
|
1.73
|
1.58
|
1.45
|
95% CI
|
0.93–1.44
|
0.83–1.43
|
0.83–3.61
|
0.86–2.90
|
0.48–4.37
|
Low-dose aspirin
|
No NSAID past 3 yearse
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
No low-dose aspirin use but use of 1+ type(s)
|
Cases, n
|
400
|
281
|
34
|
33
|
10
|
HRR
|
0.99
|
0.93
|
1.21
|
1.19
|
2.59
|
95% CI
|
0.82–1.19
|
0.75–1.17
|
0.64–2.29
|
0.63–2.25
|
0.75–8.94
|
Former/irregular
|
Cases, n
|
104
|
71
|
7
|
6
|
4
|
HRR
|
0.95
|
0.88
|
1.06
|
0.70
|
1.55
|
95% CI
|
0.75–1.19
|
0.67–1.16
|
0.45–2.50
|
0.29–1.67
|
0.48–4.99
|
Current, 3+ tablets/week
|
Cases, n
|
338
|
230
|
33
|
31
|
10
|
HRR
|
0.84
|
0.80
|
1.37
|
0.96
|
1.06
|
95% CI
|
0.72–0.98
|
0.66–0.96
|
0.81–2.32
|
0.59–1.55
|
0.46–2.45
|
Unknown
|
Cases, n
|
101
|
67
|
11
|
13
|
3
|
HRR
|
0.84
|
0.73
|
2.12
|
1.61
|
0.93
|
95% CI
|
0.62–1.14
|
0.50–1.07
|
0.84–5.34
|
0.68–3.79
|
0.19–4.68
|
Regular-dose aspirin
|
No NSAID past 3 yearse
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
No regular-dose aspirin use but use of 1+ type(s)
|
Cases, n
|
587
|
395
|
53
|
51
|
19
|
HRR
|
0.96
|
0.90
|
1.35
|
1.19
|
2.10
|
95% CI
|
0.80–1.16
|
0.72–1.12
|
0.72–2.51
|
0.64–2.22
|
0.65–6.82
|
Former/irregular
|
Cases, n
|
73
|
59
|
4
|
4
|
1
|
HRR
|
1.12
|
1.27
|
1.03
|
1.03
|
0.96
|
95% CI
|
0.84–1.50
|
0.91–1.77
|
0.32–3.31
|
0.34–3.13
|
0.11–8.30
|
Current, 3+ tablets/week
|
Cases, n
|
170
|
119
|
18
|
14
|
3
|
HRR
|
0.97
|
0.95
|
1.68
|
1.02
|
0.84
|
95% CI
|
0.80–1.18
|
0.75–1.20
|
0.90–3.17
|
0.54–1.93
|
0.24–3.03
|
Unknown
|
Cases, n
|
113
|
76
|
10
|
14
|
4
|
HRR
|
1.13
|
1.04
|
1.70
|
2.21
|
2.35
|
95% CI
|
0.83–1.54
|
0.72–1.52
|
0.60–4.81
|
0.91–5.37
|
0.29–18.94
|
Ibuprofen
|
No NSAID past 3 yearse
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
No ibuprofen use but use of 1+ type(s)
|
Cases, n
|
472
|
317
|
43
|
44
|
19
|
HRR
|
0.96
|
0.92
|
1.14
|
1.19
|
2.22
|
95% CI
|
0.80–1.15
|
0.74–1.15
|
0.61–2.14
|
0.64–2.23
|
0.69–7.16
|
Former/irregular
|
Cases, n
|
93
|
68
|
9
|
5
|
0
|
HRR
|
0.95
|
1.00
|
1.29
|
0.65
| |
95% CI
|
0.74–1.23
|
0.74–1.35
|
0.56–2.97
|
0.24–1.76
| |
Current, 3+ tablets/week
|
Cases, n
|
263
|
190
|
20
|
20
|
4
|
HRR
|
1.04
|
1.09
|
1.00
|
0.90
|
0.66
|
95% CI
|
0.88–1.23
|
0.90–1.34
|
0.54–1.84
|
0.51–1.58
|
0.21–2.10
|
Unknown
|
Cases, n
|
115
|
74
|
13
|
14
|
4
|
HRR
|
1.30
|
1.12
|
2.59
|
1.97
|
1.18
|
95% CI
|
0.99–1.70
|
0.79–1.56
|
1.16–5.79
|
0.90–4.31
|
0.19–7.46
|
Other non-steroidal
|
No NSAID past 3 yearse
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
No other non-steroidal use but use of 1+ type(s)
|
Cases, n
|
662
|
456
|
57
|
59
|
20
|
HRR
|
0.96
|
0.91
|
1.21
|
1.21
|
2.05
|
95% CI
|
0.80–1.15
|
0.73–1.13
|
0.65–2.25
|
0.65–2.26
|
0.63–6.63
|
Former/irregular
|
Cases, n
|
64
|
38
|
7
|
6
|
3
|
HRR
|
0.98
|
0.77
|
1.62
|
1.41
|
3.14
|
95% CI
|
0.72–1.33
|
0.52–1.13
|
0.62–4.20
|
0.54–3.64
|
0.78–12.72
|
Current, 3+ tablets/week
|
Cases, n
|
96
|
75
|
8
|
4
|
0
|
HRR
|
0.79
|
0.85
|
0.97
|
0.43
| |
95% CI
|
0.62–1.00
|
0.64–1.13
|
0.41–2.25
|
0.15–1.26
| |
Unknown
|
Cases, n
|
121
|
80
|
13
|
14
|
4
|
HRR
|
1.17
|
1.00
|
2.74
|
1.91
|
1.94
|
95% CI
|
0.86–1.58
|
0.69–1.45
|
1.09–6.87
|
0.79–4.62
|
0.38–9.87
|
Cox-2 inhibitor
|
No NSAID past 3 yearse
|
Cases, n
|
514
|
349
|
35
|
55
|
17
|
HRR
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
No Cox-2 inhibitor use, but use of 1+ type(s)
|
Cases, n
|
706
|
492
|
59
|
59
|
19
|
HRR
|
0.96
|
0.90
|
1.22
|
1.22
|
2.68
|
95% CI
|
0.80–1.15
|
0.72–1.12
|
0.66–2.27
|
0.66–2.28
|
0.78–9.17
|
Former/irregular
|
Cases, n
|
82
|
57
|
8
|
6
|
4
|
HRR
|
1.02
|
0.97
|
1.64
|
1.16
|
3.81
|
95% CI
|
0.78–1.34
|
0.70–1.34
|
0.68–3.97
|
0.46–2.96
|
1.07–13.57
|
Current, 3+ tablets/week
|
Cases, n
|
30
|
15
|
5
|
4
|
1
|
HRR
|
0.92
|
0.63
|
2.60
|
1.74
|
1.74
|
95% CI
|
0.63–1.34
|
0.37–1.07
|
0.97–7.00
|
0.61–4.99
|
0.22–13.66
|
Unknown
|
Cases, n
|
125
|
85
|
13
|
14
|
3
|
HRR
|
1.19
|
1.09
|
3.08
|
1.94
|
0.88
|
95% CI
|
0.88–1.61
|
0.75–1.58
|
1.21–7.88
|
0.79–4.75
|
0.15–5.22
|
-
aCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for age at menarche, parity and age at first full-term pregnancy, total months breastfeeding their offspring, history of a benign breast biopsy, family history of breast cancer (mother or sister), strenuous plus moderate physical activity, alcohol consumption, body mass index, menopausal status and hormone therapy use, and (except for “Any NSAID”) all of the other NSAIDS in the table (for each type: never past 3 years, former/irregular, current 3+ tablets/week, unknown). bCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for parity and age at first full-term pregnancy, body mass index, and (except for “Any NSAID”) all of the other NSAIDS in the table. cCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for race, alcohol consumption and its interaction with time-dependent age, and (except for “Any NSAID”) all of the other NSAIDS in the table. dCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for total months breastfeeding their offspring, history of a benign breast biopsy, and (except for “Any NSAID”) all of the other NSAIDS in the table. eIncluded aspirin, low-dose aspirin, ibuprofen, Cox-2 inhibitor, and other NSAIDs currently used regularly (at least once a week) reported on the 10-year follow-up questionnaire. NSAID non-steroidal anti-inflammatory drug, HRR hazard rate ratio, CI confidence interval